Mn-containing nanoparticle adjuvant and preparation method thereof

The preparation of multivalent Mn nanoparticle adjuvant by reacting potassium permanganate with alcohol compounds has solved the cumbersome synthesis and diffusion problems of existing manganese-based adjuvant, achieved efficient immune enhancement effects, and stimulated a powerful antigen-specific immune response and immune memory.

CN120514840APending Publication Date: 2025-08-22SHANGHAI NAKE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510663818.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-22
Publication Date
2025-08-22

AI Technical Summary

Technical Problem

The existing manganese-based adjuvant synthesis process is cumbersome and expensive, and the soluble Mn element spreads rapidly in the body, making it difficult to effectively activate the powerful cellular immune response, limiting its application in vaccines.

Method used

Potassium permanganate reacts with alcohol compounds to prepare multivalent Mn nanoparticle adjuvant, which enhances the uptake and presentation efficiency of antigen presenting cells by regulating the cGAS-STING pathway, and simplifies the preparation method and significantly enhances the immunoefficacy.

Benefits of technology

The prepared nanoparticle adjuvant significantly improved the antigen binding performance, and the specific antigen loading efficiency reached more than 90%, successfully stimulating the specific immune response and immune memory of mice, and enhancing the immune response of CD8+ T cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120514840A_ABST
    Figure CN120514840A_ABST
Patent Text Reader

Abstract

The invention discloses a Mn-containing nanoparticle adjuvant and a preparation method thereof, and belongs to the technical field of biomedical materials and immune regulation. And the Mn-containing nanoparticle adjuvant is composed of a composite oxide of multivalent manganese. The manganese-based nano adjuvant developed by the invention is simple and controllable in preparation process, adopts environment-friendly raw materials, and has excellent antigen encapsulation efficiency. The immune activation mechanism effectively starts a natural immune response system of an organism mainly by regulating and controlling a cGAS-STING signal transduction pathway. As a novel vaccine vector, the nano adjuvant can efficiently deliver specific antigens, significantly improve the endocytosis efficiency of antigen presenting cells, and promote the generation of effects such as immunogenic cell death.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a Mn-containing nanoparticle adjuvant and a preparation method thereof, and belongs to the technical field of biomedical materials and immune regulation. Background Art

[0002] As a vital weapon in modern medicine against pathogens, vaccines have been a core barrier to safeguarding public health since their inception. Vaccine systems typically consist of a core antigen component and a synergistic excipient. The core of their research and development lies in optimizing antigen presentation efficiency and enhancing immune activation. Currently, biomedical materials, as delivery vehicles, demonstrate unique advantages in the field of antigen presentation. While aluminum adjuvants can effectively promote a better immune response to antigens, they struggle to induce a robust cellular immune response, limiting their scope of clinical application. This has prompted the scientific research community to accelerate the exploration of new adjuvant systems that are both safe and highly effective.

[0003] Manganese ions, with their unique immunomodulatory properties, enhance both humoral and cellular immune responses by activating the cyclic guanosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway, demonstrating a dual immunopotentiating effect in antiviral vaccine development. However, the synthesis of conventional manganese-based adjuvants is cumbersome and costly, and the soluble Mn element rapidly diffuses in the body, significantly weakening its immunopotentiating effects. Summary of the Invention

[0004] The purpose of the present invention is: to address the deficiencies of the existing technology, the present invention provides a Mn nanoparticle adjuvant and a preparation method. The adjuvant is a new immunomodulator based on a multivalent manganese-based complex. The complex contains a multivalent Mn nanoparticle structure and a weakly crystalline or amorphous structure. By regulating the cGAS-STING pathway, it can significantly enhance the uptake and presentation efficiency of antigenic substances by antigen-presenting cells, thereby inducing an adaptive immune response.

[0005] In order to achieve the above object, the present invention provides a manganese-containing adjuvant, which includes a multivalent Mn element; the manganese-containing adjuvant is prepared by an oxidation-reduction reaction between potassium permanganate and an alcohol compound; the multivalent Mn element is Mn 2+ , Mn 3+ , and Mn 4 + .

[0006] Preferably, the manganese-containing adjuvant is in the form of nanoparticles or distributed in an amorphous state.

[0007] Preferably, the manganese-containing adjuvant further comprises O element and K element.

[0008] The present invention also provides a method for preparing the manganese-containing adjuvant, comprising: dissolving potassium permanganate powder in deionized water, mixing with an alcohol compound for reaction, centrifuging to obtain a precipitate after the reaction, and washing and drying the precipitate to obtain the manganese-containing adjuvant.

[0009] Preferably, the reaction temperature is 10-50°C and the reaction time is 10 min-2 h.

[0010] Preferably, the alcohol compound used is a monohydric alcohol and / or a polyhydric alcohol.

[0011] Preferably, the monohydric alcohol is at least one of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, sec-butanol and tert-butanol; and the polyhydric alcohol is at least one of ethylene glycol, glycerol, threitol and adonitol.

[0012] Preferably, the feeding ratio of the potassium permanganate powder to deionized water is 5-50 mg:1 ml.

[0013] Preferably, the feeding ratio of the potassium permanganate powder to the alcohol compound is 5-50 mg:1 ml.

[0014] The present invention also provides the use of the above-mentioned manganese-containing adjuvant as an immunostimulator and / or immunopotentiator in the preparation of vaccine preparations.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] The manganese nanoparticle adjuvant provided by the present invention is used as an immunopotentiator, successfully overcoming the technical bottleneck of the cumbersome synthesis process of traditional manganese adjuvants; experimental results show that the preparation has excellent antigen binding performance, and its specific antigen loading efficiency can reach more than 90%, which is significantly better than similar products; after two vaccinations, the specific immune response of mice was successfully aroused; under the restimulation of the peptide segment, CD8 + T cells secreted IFN-γ and Perforin (Mn@OVA group). In contrast, free OVA or Al@OVA had no effect. In addition, after two vaccinations, the immune memory of mice was also enhanced, and TCM and TEM were improved to a certain extent. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a transmission electron micrograph of the manganese-containing granular adjuvant prepared in Example 4 of the present invention;

[0018] Figure 2 This is a transmission electron micrograph of the manganese-containing granular adjuvant prepared in Example 5 of the present invention;

[0019] Figure 3This is a transmission electron micrograph of the manganese-containing granular adjuvant prepared in Example 6 of the present invention;

[0020] Figure 4 This is a transmission electron micrograph of the manganese-containing granular adjuvant prepared in Example 7 of the present invention;

[0021] Figure 5 This is a transmission electron micrograph of the manganese-containing granular adjuvant prepared in Example 8 of the present invention;

[0022] Figure 6 This is a transmission electron micrograph of the manganese-containing granular adjuvant prepared in Example 9 of the present invention;

[0023] Figure 7 This is a transmission electron micrograph of the manganese-containing granular adjuvant prepared in Example 10;

[0024] Figure 8 This is a mapping element scan of the manganese-containing granular adjuvant prepared in Example 3;

[0025] Figure 9 This is the valence distribution diagram of the Mn element of the manganese-containing granular adjuvant prepared in Example 3;

[0026] Figure 10 The vaccine prepared with the manganese-containing granule adjuvant prepared in Example 4 of the invention stimulated a specific immune response in mice;

[0027] Figure 11 The vaccine prepared with the manganese-containing granule adjuvant prepared in Example 4 of the invention enhances the immune memory effect of mice. DETAILED DESCRIPTION

[0028] To make the present invention more clearly understood, preferred embodiments are described in detail below with reference to the accompanying drawings.

[0029] The experimental methods in the following examples, where specific conditions are not specified, were generally performed under conventional conditions or the conditions recommended by the manufacturers. The materials and reagents used in the following examples, unless otherwise specified, were obtained from commercial sources.

[0030] Example 1 Preparation of manganese-containing adjuvant at a reaction concentration of 10 mg / mL

[0031] Dissolve 100 mg of potassium permanganate in 10 mL of deionized water, add 10 mL of ethanol solution, react at room temperature for 30 minutes, then centrifuge to obtain a precipitate, wash with deionized water, and dry in an oven (40° C.-70° C.) to obtain a manganese-containing granular adjuvant.

[0032] Example 2 Preparation of manganese-containing adjuvant at a reaction concentration of 20 mg / mL

[0033] Dissolve 200 mg of potassium permanganate in 10 mL of deionized water, add 10 mL of ethanol solution, react at room temperature for 30 minutes, then centrifuge to obtain a precipitate, wash with deionized water, and dry in an oven (40° C.-70° C.) to obtain a manganese-containing granular adjuvant.

[0034] Example 3 Preparation of manganese-containing adjuvant at a reaction concentration of 30 mg / mL

[0035] Dissolve 300 mg of potassium permanganate in 10 mL of deionized water, add 10 mL of ethanol solution, react at room temperature for 30 minutes, then centrifuge to obtain a precipitate, wash with deionized water, and dry in an oven (40° C.-70° C.) to obtain a manganese-containing granular adjuvant.

[0036] Example 4 Preparation of manganese-containing adjuvant at a reaction concentration of 40 mg / mL

[0037] Dissolve 400 mg of potassium permanganate in 10 mL of deionized water, add 10 mL of ethanol solution, react at room temperature for 30 minutes, then centrifuge to obtain a precipitate, wash with deionized water, and dry in an oven (40° C.-70° C.) to obtain a manganese-containing granular adjuvant.

[0038] Example 5 Preparation of manganese-containing adjuvant using methanol as reducing agent

[0039] Dissolve 400 mg of potassium permanganate in 10 mL of deionized water, add 10 mL of methanol solution, react at room temperature for 30 minutes, then centrifuge to obtain a precipitate, wash with deionized water, and dry in an oven (40° C.-70° C.) to obtain a manganese-containing granular adjuvant.

[0040] Example 6 Preparation of manganese-containing adjuvant using isopropyl alcohol as reducing agent

[0041] Dissolve 400 mg of potassium permanganate in 10 mL of deionized water, add 10 mL of isopropanol solution, react at room temperature for 30 minutes, then centrifuge to obtain a precipitate, wash with deionized water, and dry in an oven (40° C.-70° C.) to obtain a manganese-containing granular adjuvant.

[0042] Example 7 Preparation of manganese-containing adjuvant using ethylene glycol as reducing agent

[0043] Dissolve 400 mg of potassium permanganate in 10 mL of deionized water, add 10 mL of ethylene glycol solution, react at room temperature for 30 minutes, then centrifuge to obtain a precipitate, wash with deionized water, and dry in an oven (40° C.-70° C.) to obtain a manganese-containing granular adjuvant.

[0044] Example 8 Preparation of manganese-containing adjuvant using glycerol as reducing agent

[0045] Dissolve 400 mg of potassium permanganate in 10 mL of deionized water, add 10 mL of glycerol solution, react at room temperature for 30 minutes, then centrifuge to obtain a precipitate, wash with deionized water, and dry in an oven (40° C.-70° C.) to obtain a manganese-containing granular adjuvant.

[0046] Example 9 Preparation of manganese-containing adjuvant using threitol as reducing agent

[0047] Dissolve 400 mg of potassium permanganate in 10 mL of deionized water, add 10 mL of threitol solution, react at room temperature for 30 minutes, then centrifuge to obtain a precipitate, wash with deionized water, and dry in an oven (40° C.-70° C.) to obtain a manganese-containing granular adjuvant.

[0048] Example 10 Preparation of manganese-containing adjuvant using Adonitol as reducing agent

[0049] Dissolve 400 mg of potassium permanganate in 10 mL of deionized water, add 10 mL of adonitol solution, and react at room temperature for 30 minutes. Then, centrifuge to obtain a precipitate, wash with deionized water, and dry in an oven (40°C-70°C) to obtain a manganese-containing granular adjuvant.

[0050] Example 11 Performance Test

[0051] TEM testing

[0052] Take a small amount of the manganese-containing nanoadjuvant prepared in Examples 4 to 10 and dissolve them in 2 ml of anhydrous ethanol. Then take 20 μl and drop it onto the TEM copper grid. After the anhydrous ethanol evaporates, use it to take TEM morphology photos. The test results are as follows: Figure 1-7 shown.

[0053] Result analysis: Figure 1-7 As shown, the prepared manganese-containing adjuvant is in the form of nanoparticles or amorphous distribution. The size distribution is uniform, and the lattice structure can be clearly observed under a high-power microscope.

[0054] Mapping element scanning test

[0055] A small amount of manganese-containing adjuvant prepared in Example 3 was taken for mapping element scanning, and the test results were as follows: Figure 8 shown.

[0056] Result analysis: According to Figure 8 As shown in the mapping scan results, manganese elements are evenly distributed on the particles.

[0057] The specific composition is: Mn content 11.81%; O content 19.00%; K content 2.37%; C content 66.82%.

[0058] Mn valence distribution test

[0059] A small amount of the manganese-containing adjuvant prepared in Example 3 was taken for XPS test analysis. The test results are as follows: Figure 9 shown.

[0060] Result analysis: According to Figure 9 The test results shown in the figure show that manganese contains three valence states, namely: Mn 2+ , Mn 3+ , Mn 4+ .

[0061] Verification of in vivo adjuvant performance:

[0062] The Mn@OVA vaccine was prepared by mixing 1 ml of Mn adjuvant (3 mg / ml) with 30 μl of 10 mg / ml OVA (chicken ovalbumin, InvivoGen, vac-stva) and stirring for 30 minutes. The Alhydrogel@OVA vaccine was prepared by mixing 200 μl of 10 mg / ml Alhydrogel (InvivoGen, vac-alu-50, an aluminum salt adjuvant), 30 μl of 10 mg / ml OVA, and 770 μl of sterile water.

[0063] This example is based on the Mn adjuvant prepared in Example 4 above, combined with OVA antigen, to induce antigen-specific immune response and immune memory response in the spleen of mice induced by manganese adjuvant vaccine, including IFN-γ + CD8 + T cells, Peforin + CD8 + T cells, CD62L + CD44 - CD8 + T cells (TCM) and CD62L - CD44 + CD8 + The changes in the cell ratio of T cells (TEM) are tested, and the specific process is as follows:

[0064] After C57BL / 6J mice were raised in an SPF animal room for one week, PBS (Ctrl), OVA, Alhydrogel@OVA, and Mn@OVA were injected subcutaneously at the back of their tails (100 μl vaccine preparation per mouse), and they were respectively recorded as Group 1, Group 2, Group 3, and Group 4 for subsequent experiments. After 14 days, a vaccine booster was injected subcutaneously at the back of the tail. After 28 days, the mice were killed, and the spleens of the mice were collected and placed in a centrifuge tube equipped with a 70 μm cell strainer. The spleens were ground with the side of the rubber head of the syringe, rinsed with PBS, and centrifuged to collect the precipitate. After treatment with red blood cell lysis buffer, the spleen single cell suspension was resuspended in cell culture medium.

[0065] 100 μl of spleen single cell suspension was added to a 96-well plate and OVA was added. 257-264 The cells were incubated with GolgiPlug (Invitrogen, final concentration 20 ng / ml) and GolgiPlug (Biolegend, final concentration 1 μg / ml) for 6 hours, and then centrifuged at 350 g for 5 minutes for subsequent flow cytometry antibody staining.

[0066] The specific steps for flow cytometry antibody staining are as follows:

[0067] 1) Stain the single-cell suspension prepared above using a mixed antibody solution containing the live / dead staining reagent LIVE / DEAD Fixable Aqua (Invitrogen) and an Fc receptor blocker (Biolegend). Incubate on ice for 20 minutes, protected from light. Centrifuge and wash once with FACS buffer.

[0068] 2) Surface antigen staining of the single-cell suspension prepared above was performed using a mixed antibody solution consisting of anti-mouse CD3 (FITC-labeled, Biolegend), anti-mouse CD8 (Brilliant Violet 711-labeled, Biolegend), anti-mouse CD62L (PE-labeled, Biolegend), and anti-mouse CD44 (Alexa Fluor 700-labeled, Biolegend). Incubate on ice for 20 minutes in the dark. After centrifugation, wash once with FACS buffer.

[0069] 3) Cells were permeabilized and fixed using the Foxp3 / Transfection Factor Staining Buffer Set (eBioscience). Intracellular antigens were stained using a mixed solution of anti-mouse IFN-γ (PE-Cy7 labeled, Biolegend) and anti-mouse Perforin (APC labeled, Biolegend). Incubate on ice for 30 minutes, protected from light. After centrifugation, the cells were washed once with FACS buffer.

[0070] 4) Add 250 μl of FACS buffer to each flow cytometer tube for flow cytometry detection.

[0071] The test results are as follows Figures 10-11 As shown in the experimental results, the Mn@OVA vaccine preparation prepared with the Mn adjuvant of the present invention has excellent antigen binding performance, and its specific antigen loading efficiency can reach more than 90%, which is significantly better than similar products. After two vaccinations, the specific immune response of mice was successfully aroused. Under the restimulation of the peptide segment, CD8 +T cells secreted IFN-γ and Perforin (Mn@OVA group). In contrast, free OVA or Al@OVA had no effect. In addition, after two vaccinations, the immune memory of mice was also enhanced, and TCM and TEM were improved to a certain extent.

[0072] The above description is only a preferred embodiment of the present invention and does not constitute any formal or substantial limitation to the present invention. It should be noted that ordinary technicians in this technical field can make several improvements and supplements without departing from the present invention, and these improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. A manganese-containing adjuvant, characterized in that It includes a multivalent Mn element; the manganese-containing adjuvant is prepared by an oxidation-reduction reaction between potassium permanganate and an alcohol compound; the multivalent Mn element is Mn 2+ , Mn 3+ , and Mn 4+ .

2. The manganese-containing adjuvant according to claim 1, characterized in that The manganese-containing adjuvant is in the form of nanoparticles or distributed in an amorphous state.

3. The manganese-containing adjuvant according to claim 1, characterized in that The manganese-containing adjuvant further comprises O element and K element.

4. The method for preparing the manganese-containing adjuvant according to any one of claims 1 to 3, characterized in that: include: Potassium permanganate powder is dissolved in deionized water, and then mixed with an alcohol compound for reaction. After the reaction, centrifugation is performed to obtain a precipitate. The obtained precipitate is washed and dried to obtain a manganese-containing adjuvant.

5. The method for preparing the manganese-containing adjuvant according to claim 4, wherein The reaction temperature is 10-50°C and the reaction time is 10 min-2 h.

6. The method for preparing the manganese-containing adjuvant according to claim 4, wherein The alcohol compound used is monohydric alcohol and / or polyhydric alcohol.

7. The method for preparing the manganese-containing adjuvant according to claim 6, wherein The monohydric alcohol is at least one of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, sec-butanol and tert-butanol; the polyhydric alcohol is at least one of ethylene glycol, glycerol, threitol and adonitol.

8. The method for preparing the manganese-containing adjuvant according to claim 4, wherein The feeding ratio of the potassium permanganate powder to deionized water is 5-50 mg:1 ml.

9. The method for preparing the manganese-containing adjuvant according to claim 4, wherein: The feeding ratio of the potassium permanganate powder to the alcohol compound is 5-50 mg:1 ml.

10. Use of the manganese-containing adjuvant according to any one of claims 1 to 3 as an immunostimulant and / or immunopotentiator in the preparation of a vaccine preparation.